Stockscreener 앱 받기
189.10
2.49%
4.60
시간 외 거래:
189.50
0.40
+0.21%
전일 마감가:
$184.50
열려 있는:
$183.98
하루 거래량:
1.39M
Relative Volume:
2.20
시가총액:
$9.53B
수익:
$338.46M
순이익/손실:
$-310.96M
주가수익비율:
-28.96
EPS:
-6.53
순현금흐름:
$-132.82M
1주 성능:
+6.83%
1개월 성능:
+23.88%
6개월 성능:
+72.41%
1년 성능:
+96.61%
1일 변동 폭
$183.69
$189.34
1주일 범위
$172.05
$189.34
52주 변동 폭
$86.99
$189.34
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
AXSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
189.10 | 9.30B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.14 | 112.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.33 | 77.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.37 | 50.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
365.46 | 46.97B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.64 | 36.99B | 4.98B | 69.59M | 525.67M | 0.5197 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | 개시 | B. Riley Securities | Buy |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 개시 | Oppenheimer | Outperform |
| 2025-04-07 | 개시 | Jefferies | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength? - Yahoo Finance
HC Wainwright Has Bullish Estimate for AXSM FY2026 Earnings - MarketBeat
Axsome begins phase III AXS-14 Forward trial for fibromyalgia management - MSN
Avoiding Lag: Real-Time Signals in (AXSM) Movement - Stock Traders Daily
Axsome Therapeutics stock hits all-time high at 184.45 USD By Investing.com - Investing.com India
Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year High on Analyst Upgrade - MarketBeat
Axsome Therapeutics stock hits all-time high at 184.45 USD - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $260.00 at HC Wainwright - MarketBeat
Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Appears In Nasdaq Today CNS Discussions - Kalkine Media
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Yahoo Finance
Piper Sandler raises Axsome Therapeutics price target to $223 on growth outlook - Investing.com UK
Axsome Therapeutics begins phase 3 trial of AXS-14 for fibromyalgia - Investing.com Nigeria
Assessing Axsome Therapeutics (AXSM) After An 86% One-Year Share Price Surge - Sahm
Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Axsome Therapeutics Initiates Forward Phase 3 Trial of AXS-14 for the Management of Fibromyalgia - marketscreener.com
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia - manilatimes.net
Axsome Therapeutics Doses First Patient in Phase 3 FORWARD Trial of AXS-14 for Fibromyalgia Management - Quiver Quantitative
Phase 3 test of AXS-14 for fibromyalgia begins at Axsome Therapeutics - Stock Titan
Cantor Fitzgerald reiterates Axsome stock rating, sees strategic potential By Investing.com - Investing.com UK
Axsome Therapeutics (AXSM) Price Target Increased by 13.75% to 207.38 - Nasdaq
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Vertex Pharmaceuticals (VRTX) and CareDx (CDNA) - The Globe and Mail
Axsome Therapeutics (BIT:1AXSM) Price Target Increased by 15.47% to 174.52 - Nasdaq
Risk Report: Is Axsome Therapeutics Inc stock trending bullishMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $190 to $225 - 富途牛牛
Baird raises Axsome Therapeutics stock price target to $209 on strong sales - Investing.com Canada
Is Axsome Therapeutics (AXSM) Pricing Reflect Long Term Growth After Pipeline Milestones And 90% Rally - Yahoo Finance
MoneyShow's Best Investment Ideas For 2026: Part 2 - Seeking Alpha
Axsome Therapeutics Preliminary Q4 Net Product Revenue Up 65% - Nasdaq
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue - The Manila Times
Iridian Asset Management LLC CT Has $10.15 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy - Chartmill
Axsome Therapeutics, Inc. $AXSM Shares Sold by Peregrine Capital Management LLC - MarketBeat
Can Axsome Therapeutics Inc. (19X) stock hold up in economic slowdown2025 Historical Comparison & Expert Approved Momentum Ideas - ulpravda.ru
Discipline and Rules-Based Execution in AXSM Response - Stock Traders Daily
Why Axsome Therapeutics Inc. stock is rated strong buyMarket Sentiment Indicators & Maximize ROI With Proven Growth Stocks - bollywoodhelpline.com
Why Axsome Therapeutics Inc. stock could outperform in 20252025 Market Overview & Verified Chart Pattern Signals - ulpravda.ru
Will Axsome Therapeutics Inc. stock reach all time highs in 2025July 2025 Drop Watch & Daily Price Action Insights - Улправда
How interest rate cuts could boost Axsome Therapeutics Inc. stock2025 Pullback Review & Weekly Top Performers Watchlists - ulpravda.ru
How Axsome Therapeutics Inc. stock reacts to Fed rate cutsBreakout Watch & Fast Gain Swing Alerts - ulpravda.ru
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - Investing.com
Biotech Is Heating Up-These 2 Red-Hot Stocks Stand Out - Finviz
Axsome Therapeutics (NASDAQ:AXSM) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - MarketBeat
Morgan Stanley Downgrades Axsome Therapeutics to Equal Weight From Overweight, Adjusts PT to $204 From $196 - marketscreener.com
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Morgan Stanley downgrades Axsome stock after 23% rally, raises price target - Investing.com Canada
Morgan Stanley Downgrades Axsome Therapeutics (AXSM) to Equal-We - GuruFocus
Axsome therapeutics CEO sells $23.8m in shares By Investing.com - Investing.com UK
Herriot Tabuteau Sells 78,703 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) CEO Sells 29,450 Shares of Stock - MarketBeat
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.17%
4.40%
자본화:
|
볼륨(24시간):